Impacted Third Molar Tooth, Post Operative Pain
Conditions
Keywords
Third molar surgery, Post Operative Pain, Paracetamol, Ibuprofen
Brief summary
In this study, the investigators recruited patients undergoing surgical removal of impacted third molar teeth. Participants will be randomly divided into two groups Group 1: The patient will receive 400mg of ibuprofen plus 1000mg of Paracetamol simultaneously every 8 hours for two days. Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day Then, pain control will be assessed using various primary and secondary outcome scales.
Detailed description
Surgical removal of an impacted mandibular third molar is one of the most common procedures in oral and maxillofacial surgery. Ten million third molars are extracted from approximately 5 million people in the United States each year. Research suggests that wisdom tooth removal has an immediate negative impact on patients' working and social lives: in one study, patients took an average of 1.6 days off work, with over one-third of patients stating that the surgery had affected their performance at work. Postoperative complications may include swelling, bruising, and limited mouth opening, along with difficulty with eating, which can be a major concern to patients and has not been appreciated by healthcare professionals in the past. However, patients are often most concerned about postoperative pain, which may be severe. Approximately one in two patients will experience pain despite analgesic therapy, even one week after surgery. The inflammatory response to surgical trauma is associated with edema, discomfort, dehiscence, and trismus, and these factors may affect the patient's everyday life. The control of these symptoms is frequently based on pharmacological manipulation of local and systemic pain and inflammation mediators. Combining two analgesic agents with distinct mechanisms or sites of action, such as combining a peripherally acting analgesic with a centrally acting analgesic, has been advocated for many years. A common example is the analgesic formulation containing acetaminophen combined with the opioid hydrocodone or paracetamol with ibuprofen. The pain control of single showed that the maximum effect is recorded in the first 2 to 3 hours. Combining two agents tends to increase the effect for 6 to 8 hours. However, as both medication actions commence simultaneously in the latter combination, they are likely to fade in the same way. This may make the patient likely to overdose on such medicine to ensure the continuity of pain relief. This research aims to test the combination of classical pain medication but in a novel alternate way to minimize the dosage and avoid the risk of side effects and toxicity.
Interventions
DRUGParacetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours
Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
DRUGParacetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours
Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
Sponsors
University of Sharjah
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Masking description
The evaluators responsible for data collection and analyses are blinded to the analgesic medication regime used by the patients
Intervention model description
A single-center, double-blind, parallel-group, randomized controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years, 2. Need for surgical extraction of at least one fully or partially impacted lower third molar with a degree of difficulty of 5 points or more on the Pedersen scale, 3. ASA I-II status according to the American Society of Anesthesiologists, and 4. No allergy to the drugs under study.
Exclusion criteria
1. Pregnancy 2. Breastfeeding 3. ASA III or above 4. Consumption of antibiotics in the week before surgery; and 5. Clinical evidence of acute infection on the day of surgical intervention 6. Radiographic evidence of peri-radicular pathology in impacted teeth requiring extraction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analogue Scale | 48 hours | Pain was analyzed in 2 ways: (1) as the mean of pain intensity VAS score evaluated at 0, 4, 8, 12, 24, 36, and 48 hours post-extraction. Range 0-10 |
| The maximum pain experienced by patients | 48 hours | a)No pain, b)Some pain, c)Noticeable pain and d)Extreme pain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Onset of pain control | 48 hours | The time to analgesic onset is defined as the time between trial drug intake and the first report of pain relief, |
| Duration of pain control | 48 hours | the time between the first report of perceptible and meaningful pain relief and pain reappearing, |
| the rescue medicine intake | 48 hours | the time from trial drug intake to the intake of the first dose of the rescue medicine |
Countries
United Arab Emirates
Outcome results
None listed